Loading clinical trials...
Loading clinical trials...
A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.
Conditions
Interventions
SPD476 (1.2g)
SPD476 (2.4 g)
+2 more
Locations
121
United States
Dedicated Clinical Research
Litchfield Park, Arizona, United States
Lynn Institute of the Ozarks
Little Rock, Arkansas, United States
Advanced Clinical Research Institute
Anaheim, California, United States
GW Research
Chula Vista, California, United States
Monterey Bay GI Research Institute, Inc
Monterey, California, United States
Rancho Cucamonga C. Trials
Rancho Cucamonga, California, United States
Start Date
November 28, 2007
Primary Completion Date
March 5, 2012
Completion Date
March 5, 2012
Last Updated
June 14, 2021
NCT05829343
NCT06344078
NCT07322926
NCT02831556
NCT06388538
NCT05393609
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions